Showing results (101-110 of 185) with videos related to

Sort By:
Pageof 19
American Journal of Hematology|January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trialEvangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2025
Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study GroupDespina Fotiou, Sorina Nicoleta Badelita, Eirini Katodritou, et al.
The Oncologist|January 21, 2010
Current multiple myeloma treatment strategies with novel agents: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
British Journal of Haematology|July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Blood|April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myelomaSarah A Holstein, Shebli Atrash, Hira Mian, et al.
American Journal of Hematology|October 24, 2025
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast NephropathyHeinz Ludwig, Meletios Athanasios Dimopoulos, Evangelos Terpos, et al.
Haematologica|October 4, 2015
European Myeloma Network guidelines for the management of multiple myeloma-related complicationsEvangelos Terpos, Martina Kleber, Monika Engelhardt, et al.
Leukemia|February 7, 2020
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)C Ola Landgren, Ajai Chari, Yael C Cohen, et al.
Pageof 19